Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Viridian Therapeutics, Inc.\DE Q3 2026 Results: Net Loss of $101M, Loss Widens

Viridian Therapeutics is transitioning toward commercialization with the submission of a Marketing Authorization Application for veligrotug in Europe and a planned BLA submission for elegrobart in early 2027. The company remains pre-profit, relying on existing cash and anticipated future revenues to fund its clinical pipeline, including new trials for VRDN-292 and its FcRn inhibitor portfolio.

Watch the Viridian Therapeutics, Inc.\DE earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue25.870.6
Net income-101.2-34.6

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-63.5%
Operating margin-401.8%
Source

10-Q filed with the SEC, NASDAQ: VRDN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Viridian Therapeutics, Inc.\DE: key numbers

Share price
$29.80Close, Nov 16
Market cap
$3.38B
Shares outstanding
113.56MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Viridian Therapeutics, Inc.\DE

All →
7:33 AM ET 8-K
Clinical Trial Data

Viridian Therapeutics, Inc.\DE Clinical Trial Data

Viridian Therapeutics announced positive Phase 1 clinical trial results for VRDN-008, a half-life extended FcRn inhibitor, which demonstrated a 74% peak reduction in IgG and a half-life 5-6 times longer than first-generation fragments. The data supports a potential best-in-class every-eight-week subcutaneous dosing regimen, and the company plans to initiate a pivotal trial in myasthenia gravis in mid-2027.

7:12 AM ET 8-K
Financial Results

Viridian Therapeutics, Inc.\DE Financial Results

Viridian Therapeutics reported third quarter 2026 financial results, highlighted by $24.7 million in net product revenue from the launch of Lumvoa (veligrotug-vvze). The company remains on track for a BLA submission for elegrobart in Q1 2027 and expects Phase 1 data for VRDN-008 in Q4 2026.

“We are highly encouraged by the strength of Lumvoa’s early launch in TED, which has exceeded expectations. These strong early results are a testament to Lumvoa’s compelling clinical profile, the extraordinary execution of our Commercial and Medical teams, and the incredible support of our broader organization.”

Steve Mahoney, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.